MEXICO CITY–(BUSINESS WIRE)–More than 40 leading ophthalmologists, vision researchers, and public health/policy experts are sharing data and holding discussions on the global burden of diabetes-related eye disease to develop a plan to address this le…
Category: Business
Oxular Limited anuncia la autorización IND de OXU-001 supracoroidal para el tratamiento del edema macular diabético
OXFORD, Reino Unido–(BUSINESS WIRE)–Oxular Limited, una empresa de dispositivos oftálmicos en fase clínica que desarrolla terapias dirigidas a largo plazo para trastornos de la retina con el fin de mejorar la visión de los pacientes, ha anunciado hoy…
Oxular Limited kondigt acceptatie aan van IND voor suprachoroïdale OXU-001 voor de behandeling van diabetisch macula-oedeem
OXFORD, Verenigd Koninkrijk–(BUSINESS WIRE)–Oxular Limited, een oogheelkundig bedrijf in de klinische fase dat langdurige, gerichte behandelingen voor netvliesaandoeningen ontwikkelt om het gezichtsvermogen van patiënten te verbeteren, heeft vandaag …
Oxular Limited annuncia l'accettazione dell'IND per OXU-001 sopracoroideale nel trattamento dell'edema maculare diabetico
OXFORD, Regno Unito–(BUSINESS WIRE)–Oxular Limited, azienda terapeutica oftalmica di fase clinica che sviluppa trattamenti mirati di lunga durata contro i disturbi della retina per migliorare la vista dei pazienti, oggi ha annunciato che la U.S. Food…
Oxular Limited gibt die Genehmigung der IND (Investigational New Drug, neues Prüfpräparat) für den suprachoroidalen Wirkstoff OXU-001 zur Behandlung des diabetischen Makulaödems bekannt
OXFORD, Vereinigtes Königreich–(BUSINESS WIRE)–Oxular Limited, ein in der klinischen Phase tätiges Unternehmen im Bereich der Augenheilkunde, das lang anhaltende, zielgerichtete Behandlungen für Netzhauterkrankungen entwickelt, um das Sehvermögen der…
Oxular Limited annonce l'autorisation DNR pour l'OXU-001 suprachoroïdien dans le traitement de l'œdème maculaire diabétique
OXFORD, Royaume-Uni–(BUSINESS WIRE)–Oxular Limited, une société de matériel ophtalmologique au stade clinique qui développe des traitements ciblés de longue durée pour les troubles rétiniens afin d’améliorer la vision des patients, a annoncé aujourd’…
Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema
OXFORD, United Kingdom–(BUSINESS WIRE)–Oxular Limited, a clinical-stage ophthalmic company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced that the U.S. Food and Drug Administration has a…
Fabrinet to Announce Second Quarter 2023 Financial Results on February 6, 2023
BANGKOK–(BUSINESS WIRE)–Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced it …
Age-Related Macular Degeneration (AMD) Global Market Report 2022: Upcoming Treatments to Redefine Sector – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Age-Related Macular Degeneration (AMD) Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis” report has been added to ResearchAndMarkets.com’s offering. Age-Related …
Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five branded ophthalmic pr…
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2022 Financial Results on February 22
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2022 financial res…
OcuSciences Announces Publication of Study Showing Novel Flavoprotein Fluorescence Measure Is Increased in Inherited Retinal Dystrophies
ANN ARBOR, Mich.–(BUSINESS WIRE)–OcuSciences, Inc., a medical device company developing retinal imagers to detect early disease by assessing retinal metabolic activity, today announced the publication of a rare inherited mitochondrial diseases study …
Alivi Health Expands into Several States
MIAMI–(BUSINESS WIRE)–Alivi Health today announced the expansion of their Non-Emergency Transportation (NET) solution into several states. Alivi is actively providing services in 13 states, and has now expanded into New York, New Jersey, Pennsylvania…
CXL Ophthalmics Appoints Jonathan Talamo, MD, as Chair of the Board
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics announces that Jonathan Talamo, MD has been appointed as its new Chair of the Board of Directors.
Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031; A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD)
PHILADELPHIA–(BUSINESS WIRE)– #biotechnology–Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-…
NTT Research to Host Upgrade 2023 Global Innovation Summit
SUNNYVALE, Calif.–(BUSINESS WIRE)– #TechforGood–NTT Research will hold Upgrade 2023, the NTT Research Summit, in-person on March 15-16, 2023, organized under the theme “Scaling the Future.”
Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects
SAN DIEGO–(BUSINESS WIRE)–Trefoil Therapeutics Announces First Patient Dosed in Phase 1 Study of TTHX1114 for Treatment of Corneal Epithelial Defects
PhaseOne Health and NovaBay Pharmaceuticals to Expand Commercial and Collaborative Strategies for the Wound Care Market
NASHVILLE, Tenn. & EMERYVILLE, Calif.–(BUSINESS WIRE)–PhaseOne Health announces the expansion of its commercial program for PhaseOne Skin and Wound Care Cleanser through collaborative partnerships with innovative wound dressing manufacturers and key …
Worldwide Ophthalmic Lasers Industry to 2029 – Rise in Eye-related Conditions Such as Refractive Errors, Cataracts and Glaucoma Drive Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lasers Market Analysis, By Application, By Type, By End User, and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic lasers market size is estimated t…
Glaucoma Surgery Devices Market Report to 2029 – Featuring Abbott Medical Optics, Topcon, Lumenis and Allergan Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma Surgery Devices Market Analysis, By Surgery Type By Product type, By End User, and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The glaucoma surgery devices mark…